

CANCER IMMUNOLOGY AND ONCOLYTIC VIROLOGY: TECHNOLOGIES AND GLOBAL MARKETS



PHM129A
March 2014

Valerie Kellogg
Project Analyst

ISBN: 1-56965-753-X

bcc | Research
Market Forecasting

BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THE STUDY	2
SCOPE OF REPORT	2
INTENDED AUDIENCE	3
INFORMATION SOURCES	3
ANALYST CREDENTIALS	3
RELATED BCC RESEARCH REPORTS	3
BCC RESEARCH ONLINE SERVICES	4
DISCLAIMER	4
CHAPTER 2 SUMMARY	6
<i>SUMMARY TABLE CANCER IMMUNOTHERAPIES MARKET BY GEOGRAPHICAL REGION, THROUGH 2018 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE CANCER IMMUNOTHERAPIES MARKET BY GEOGRAPHICAL REGION, 2011-2018 (\$ MILLIONS)</i>	7
CHAPTER 3 OVERVIEW	9
HISTORY AND CURRENT STATE OF CANCER IMMUNOLOGY	9
CANCER TYPES	9
TYPES OF CANCER TREATMENT	10
Surgery	10
Radiation Therapy	10
Pharmaceutical Therapy	11
Immunotherapy	11
Inflammatory Response	11
WHY IS CANCER SO DIFFICULT TO CURE?	12
Treatment-resistant Cancer	12
Strategies to Improve Response and Decrease Mortality	13
Pre-emptive Therapy	13
Early Stage vs. Advanced Cancer	13
MOST CLINICALLY SIGNIFICANT HUMAN CANCERS	14
Prostate Cancer	14
<i>TABLE 1 GLOBAL PROSTATE CANCER INCIDENCE AND MORTALITY, 2012</i>	14
Diagnosis	15
Treatment	15
Prognosis	15
Chronic Lymphocytic Leukemia (CLL)	16
<i>TABLE 2 GLOBAL LEUKEMIA INCIDENCE AND MORTALITY, 2012</i>	16
Diagnosis	17
Treatment	17
Prognosis	17
Breast Cancer	17
<i>TABLE 3 GLOBAL BREAST CANCER INCIDENCE AND MORTALITY, 2012 (THOUSANDS)</i>	18
<i>TABLE 4 BREAST CANCER INCIDENCE, 2012 (NUMBER)</i>	18

TOPIC	PAGE NO.
Diagnosis	18
Treatment	19
Prognosis	19
<i>TABLE 5 PROGNOSIS OF BREAST CANCER BASED UPON STAGE (%)</i>	20
Metastatic Melanoma	20
<i>TABLE 6 GLOBAL MELANOMA CANCER INCIDENCE AND MORTALITY, 2012 (NUMBER)</i>	20
Diagnosis	21
Treatment	22
Prognosis	22
Ovarian Cancer	23
<i>TABLE 7 GLOBAL OVARIAN CANCER INCIDENCE AND MORTALITY, 2012 (NUMBER)</i>	23
Diagnosis	23
Treatment	24
Prognosis	24
<i>TABLE 8 RELATIVE FIVE-YEAR SURVIVAL RATE FOR INVASIVE EPITHELIAL OVARIAN CANCER (%)</i>	25
Cervical Cancer	25
<i>TABLE 9 GLOBAL CERVICAL CANCER INCIDENCE AND MORTALITY, 2012 (NUMBER)</i>	25
Diagnosis	27
Treatment	27
<i>TABLE 10 AVASTIN SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	28
Prognosis	28
<i>TABLE 11 FIVE-YEAR RELATIVE SURVIVAL OF CERVIX UTERI CANCER PATIENTS, BASED ON STAGE AT DIAGNOSIS (%)</i>	29
Head and Neck Cancer	29
Diagnosis	30
Treatment	30
Prognosis	30
Lung Cancer	30
<i>TABLE 12 GLOBAL LUNG CANCER INCIDENCE AND MORTALITY, 2012 (THOUSANDS)</i>	30
Diagnosis	31
<i>TABLE 13 STAGES OF LUNG CANCER</i>	31
Treatment	31
Prognosis	32
<i>TABLE 14 NON-SMALL CELL LUNG CANCER FIVE-YEAR SURVIVAL RATES BY STAGE (%)</i>	32
Brain Cancer	32
<i>TABLE 15 GLOBAL BRAIN CANCER INCIDENCE AND MORTALITY, 2012 (THOUSANDS)</i>	33
Diagnosis	33
Treatment	33
Prognosis	34
Multiple Myeloma	34
<i>TABLE 16 GLOBAL MULTIPLE MYELOMA CANCER INCIDENCE AND MORTALITY, 2012 (THOUSANDS)</i>	34
Diagnosis	35
Treatment	35
Prognosis	35
Pancreatic Cancer	35

TOPIC	PAGE NO.
<i>TABLE 17 GLOBAL PANCREATIC CANCER INCIDENCE AND MORTALITY, 2012 (THOUSANDS)</i>	36
Diagnosis	36
Treatment	36
Prognosis	37
<i>TABLE 18 EXOCRINE PANCREATIC CANCER FIVE-YEAR SURVIVAL RATE (%)</i>	37
SUMMARY OF GLOBAL HUMAN CANCER TRENDS THROUGH 2018	37
<i>TABLE 19 GLOBAL HUMAN CANCER TRENDS, 2011-2018 (NUMBER OF CASES)</i>	38
<i>FIGURE 1 GLOBAL HUMAN CANCER TRENDS, 2011-2018 (NUMBER OF CASES)</i>	38
<i>TABLE 20 U.S. HUMAN CANCER TRENDS, 2011-2018 (NUMBER OF CASES)</i>	38
<i>TABLE 21 CANADIAN HUMAN CANCER TRENDS, 2011-2018 (NUMBER OF CASES)</i>	39
<i>TABLE 22 EUROPEAN HUMAN CANCER TRENDS, 2011-2018 (NUMBER OF CASES)</i>	39
<i>TABLE 23 JAPANESE HUMAN CANCER TRENDS, 2011-2018 (NUMBER OF CASES)</i>	40
<i>TABLE 24 REST OF WORLD HUMAN CANCER TRENDS, 2011-2018 (NUMBER OF CASES)</i>	41
CIRCUMSTANCES MOST LIKELY TO LEAD TO ADVANCED CANCERS	41
Genetics	41
Exposure to Radiation	41
Exposure to a Chemical Carcinogen	42
<i>TABLE 25 KNOWN OCCUPATIONAL EXPOSURE RISKS ASSOCIATED WITH CANCER</i>	42
Exposure to a Biological Carcinogen	43
HUMAN CANCER R&D	43
CHAPTER 4 OVERVIEW OF CANCER IMMUNOTHERAPY	45
MECHANISMS OF ACTION	45
HUMAN IMMUNE SYSTEM	45
T CELLS	46
PD-1 AND PD-L1 BLOCKERS	46
BIOLOGICAL RESPONSE MODIFIERS	47
COLONY-STIMULATING FACTORS	47
<i>TABLE 26 COLONY-STIMULATING FACTORS ON THE MARKET</i>	48
INTERFERONS	49
<i>TABLE 27 SELECTED INTERFERON PRODUCTS ON THE MARKET</i>	49
INTERLEUKIN PRODUCTS	50
<i>TABLE 28 SELECTED DEVELOPMENTS IN INTERLEUKINS FOR CANCER THERAPY</i>	51
THERAPEUTIC MONOCLONAL ANTIBODIES	51
<i>TABLE 29 SELECTED APPROVED MONOCLONAL ANTIBODIES</i>	52
<i>TABLE 30 ELECTED MABS IN CLINICAL TESTING FOR INITIAL APPROVAL OR FOR ADDITIONAL INDICATIONS</i>	54
CANCER VACCINES	56
VACCINES TO PROTECT AGAINST CANCER	56
THERAPEUTIC CANCER VACCINES	57
Melanoma	57
Breast Cancer	57
Cervical Cancer	57
Ovarian Cancer	58
Renal Cell Carcinoma	58
Lung Cancer	58

TOPIC	PAGE NO.
Pancreatic Cancer	59
Prostate Cancer	59
Sipuleucel-T	59
DCVax-Prostate	60
OTHER IMMUNOTHERAPY PRODUCTS FOR CANCER TREATMENT	60
GLEEVEC	61
IRESSA	61
KYPROLIS	61
NEXAVAR	61
POMALYST	62
SUTENT	62
TARCEVA	62
TYKERB	62
VELCADE	63
<i>TABLE 31 SELECTED CLINICAL TRIALS OF IMMUNOTHERAPY PRODUCTS</i>	63
EXPANDED INFORMATION REGARDING SELECTED CLINICAL TRIALS	69
ROCHE'S MPDL3280A TRIAL	69
AMGEN'S ASPECCT TRIAL	70
SEATTLE GENETICS, MILLENNIUM/TAKEDA TRIAL OF ADCETRIS (NCT01896999)	70
BMS AND ABBVIE'S ELOQUENT-1 AND -2 TRIALS	70
BMS AND NIVOLUMAB WITH OR WITHOUT YERVOY	70
BMS AND YERVOY FOR METASTATIC PROSTATE CANCER	71
MERCK AND LAMBROLIZUMAB (MK-3475)	71
CHAPTER 5 ONCOLYTIC VIROTHERAPY	74
VIROTHERAPY	74
ONCOLYTIC VIROLOGY	74
USING HIV TO TREAT CANCER	75
TREATING PEDIATRIC CANCERS WITH VIRUSES	75
CORPORATE DEVELOPMENTS IN ONCOLYTIC VIROLOGY	76
BioVex, Amgen and Talimogene Laherparepvec	76
Oncorine	76
DNX-2401	76
PV701 and Newcastle-Disease Virus (NDV)	77
Picornaviruses	77
NEWS AND DEALS IN CANCER IMMUNOTHERAPY AND VIROLOGY	77
NOVARTIS, UNIVERSITY OF PENNSYLVANIA AND CART TECHNOLOGY	77
CELGENE AND ONCOMED PHARMACEUTICALS	78
SEATTLE GENETICS	78
BRISTOL-MYERS SQUIBB	78
MERCK & CO. AND GSK	79
TAKEDA'S MAB LICENSING DEAL WITH IMMUNOMEDICS	79
GENENTECH/ROCHE AND PERTUZUMAB	80
MERCK KGAA AND STIMUVAX	80
ROCHE AND IMMATICS BIOTECHNOLOGIES GMBH SIGN COLLABORATION DEAL	80
MEDIGENE AG AND TRIANTA IMMUNOTHERAPIES	81

TOPIC	PAGE NO.
GOVERNMENT REGULATIONS	81
U.S. FOOD AND DRUG ADMINISTRATION	81
FDA AND BREAKTHROUGH THERAPY DESIGNATION (BTD)	81
EUROPEAN REGULATORY AUTHORITIES	82
THE U.K.'S VERSION OF THE FDA'S BTD	82
INDUSTRY STRUCTURE	82
MAJOR COMPANIES AND MARKET SHARE	82
FIGURE 2 MARKET SHARES OF LEADERS IN CANCER IMMUNOLOGY, 2013 (%)	82
ONCOLYTIC VIROLOGY COMPANIES	83
CHAPTER 6 MAJOR MARKETS	85
TABLE 32 GLOBAL MARKET FOR CANCER IMMUNOLOGY BY SEGMENT, THROUGH 2018 (\$ MILLIONS)	85
TABLE 33 VALUE OF CANCER IMMUNOLOGY PRODUCTS IN THE U.S., THROUGH 2018 (\$ MILLIONS)	85
TABLE 34 VALUE OF CANCER IMMUNOLOGY PRODUCTS IN CANADA THROUGH 2018 (\$ MILLIONS)	86
TABLE 35 VALUE OF CANCER IMMUNOLOGY PRODUCTS IN THE EU THROUGH 2018 (\$ MILLIONS)	86
TABLE 36 VALUE OF CANCER IMMUNOLOGY PRODUCTS IN JAPAN, THROUGH 2018 (\$ MILLIONS)	87
TABLE 37 VALUE OF CANCER IMMUNOLOGY PRODUCTS FOR REST OF WORLD, (THROUGH 2018) (\$ MILLIONS)	87
TABLE 38 CANCER IMMUNOLOGY MARKET BY INDICATION, THROUGH 2018 (\$ MILLIONS)	88
TABLE 39 CANCER IMMUNOLOGY SALES BY INDICATION (PROSTATE CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 (\$ MILLIONS)	88
TABLE 40 CANCER IMMUNOLOGY SALES BY INDICATION (BREAST CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 (\$ MILLIONS)	89
TABLE 41 CANCER IMMUNOLOGY SALES BY INDICATION (LUNG CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 (\$ MILLIONS)	89
TABLE 42 CANCER IMMUNOLOGY SALES BY INDICATION (BRAIN CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 (\$ MILLIONS)	90
TABLE 43 CANCER IMMUNOLOGY SALES BY INDICATION (HEAD & NECK CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 (\$ MILLIONS)	90
TABLE 44 CANCER IMMUNOLOGY SALES BY INDICATION (OVARIAN CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 (\$ MILLIONS)	91
TABLE 45 CANCER IMMUNOLOGY SALES BY INDICATION (CERVICAL CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 (\$ MILLIONS)	91
TABLE 46 CANCER IMMUNOLOGY SALES BY INDICATION (PANCREATIC CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 (\$ MILLIONS)	91
TABLE 47 CANCER IMMUNOLOGY SALES BY INDICATION (MELANOMA CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 (\$ MILLIONS)	92
TABLE 48 CANCER IMMUNOLOGY SALES BY INDICATION (OTHER CANCERS) AND GEOGRAPHIC REGION, THROUGH 2018 (\$ MILLIONS)	92
TABLE 49 CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: COLONY STIMULATING FACTORS, THROUGH 2018 (\$ MILLIONS)	93
TABLE 50 CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: INTERFERON ALFA AND GAMMA PRODUCTS, THROUGH 2018 (\$ MILLIONS)	93
TABLE 51 CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: INTERLEUKIN PRODUCTS, THROUGH 2018 (\$ MILLIONS)	93

TOPIC	PAGE NO.
<i>TABLE 52 CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: THERAPEUTIC MONOCLONAL ANTIBODIES, THROUGH 2018 (\$ MILLIONS)</i>	94
<i>TABLE 53 CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: CANCER VACCINES, THROUGH 2018 (\$ MILLIONS)</i>	94
<i>TABLE 54 CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: OTHER CANCER TREATMENT IMMUNOTHERAPY PRODUCTS, THROUGH 2018 (\$ MILLIONS)</i>	95
MARKET FOR ONCOLYTIC VIROLOGY PRODUCTS	95
<i>TABLE 55 GLOBAL ONCOLYTIC VIROTHERAPY MARKET, THROUGH 2023 (\$ MILLIONS)</i>	95
<i>TABLE 56 ONCOLYTIC VIROTHERAPY MARKET BY REGION, THROUGH 2023 (\$ MILLIONS)</i>	96
<i>TABLE 57 ONCOLYTIC VIROLOGY OUTLOOK BY CANCER TYPE, THROUGH 2023 (\$ MILLIONS)</i>	96
CHAPTER 7 TECHNOLOGY	98
PRODUCTION OF MONOCLONAL ANTIBODIES	98
ANTIBODY-DRUG CONJUGATES	98
CAR T-CELL TECHNOLOGY	99
PATENT EVALUATION	99
CANADA AND MONOCLONAL ANTIBODIES	99
INDIA AND (LACK OF) INTELLECTUAL PROPERTY PROTECTION	99
NEWLY ISSUED PATENTS	100
<i>TABLE 58 SELECTED PATENTS IN CANCER IMMUNOLOGY AND VIROLOGY, 2005 TO 2013</i>	100
CHAPTER 8 COMPANY PROFILES	103
SELECTED COMPANY PROFILES	103
ABLYNX NV	103
ADURO BIOTECH, INC.	103
ADVAXIS INC.	104
ASTRAZENECA U.S.	104
BRISTOL-MYERS SQUIBB	104
CELGENE CORP.	105
DENDREON CORP.	105
DNATRIX, INC.	106
GENENTECH, A MEMBER OF THE ROCHE GROUP	106
GLAXOSMITHKLINE	107
GLOBEIMMUNE, INC.	107
IMMATICS BIOTECHNOLOGIES GMBH	107
IMMUNOMEDICS, INC.	108
IMMUNOVACCINE, INC.	108
JANSSEN BIOTECH INC./JOHNSON & JOHNSON	109
JENNEREX BIOTHERAPEUTICS INC.	109
MEDIMMUNE LLC (ASTRAZENECA)	109
MEDIVATION INC.	110
MERCK & CO.	110
NORTHWEST BIOTHERAPEUTICS, INC.	111
NOVARTIS INTERNATIONAL AG	111

TOPIC	PAGE NO.
NOVARTIS PHARMACEUTICALS CORP.	112
ONCOMED PHARMACEUTICALS INC.	112
PFIZER INC.	112
ROCHE (F. HOFFMAN-LA ROCHE AG)	113
VIRALYTICS, LTD.	113

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE CANCER IMMUNOTHERAPIES MARKET BY GEOGRAPHICAL REGION, THROUGH 2018 (\$ MILLIONS)	7
TABLE 1 GLOBAL PROSTATE CANCER INCIDENCE AND MORTALITY, 2012	14
TABLE 2 GLOBAL LEUKEMIA INCIDENCE AND MORTALITY, 2012	16
TABLE 3 GLOBAL BREAST CANCER INCIDENCE AND MORTALITY, 2012 (THOUSANDS)	18
TABLE 4 BREAST CANCER INCIDENCE, 2012 (NUMBER)	18
TABLE 5 PROGNOSIS OF BREAST CANCER BASED UPON STAGE (%)	20
TABLE 6 GLOBAL MELANOMA CANCER INCIDENCE AND MORTALITY, 2012 (NUMBER)	20
TABLE 7 GLOBAL OVARIAN CANCER INCIDENCE AND MORTALITY, 2012 (NUMBER)	23
TABLE 8 RELATIVE FIVE-YEAR SURVIVAL RATE FOR INVASIVE EPITHELIAL OVARIAN CANCER (%)	25
TABLE 9 GLOBAL CERVICAL CANCER INCIDENCE AND MORTALITY, 2012 (NUMBER)	25
TABLE 10 AVASTIN SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)	28
TABLE 11 FIVE-YEAR RELATIVE SURVIVAL OF CERVIX UTERI CANCER PATIENTS, BASED ON STAGE AT DIAGNOSIS (%)	29
TABLE 12 GLOBAL LUNG CANCER INCIDENCE AND MORTALITY, 2012 (THOUSANDS)	30
TABLE 13 STAGES OF LUNG CANCER	31
TABLE 14 NON-SMALL CELL LUNG CANCER FIVE-YEAR SURVIVAL RATES BY STAGE (%)	32
TABLE 15 GLOBAL BRAIN CANCER INCIDENCE AND MORTALITY, 2012 (THOUSANDS)	33
TABLE 16 GLOBAL MULTIPLE MYELOMA CANCER INCIDENCE AND MORTALITY, 2012 (THOUSANDS)	34
TABLE 17 GLOBAL PANCREATIC CANCER INCIDENCE AND MORTALITY, 2012 (THOUSANDS)	36
TABLE 18 EXOCRINE PANCREATIC CANCER FIVE-YEAR SURVIVAL RATE (%)	37
TABLE 19 GLOBAL HUMAN CANCER TRENDS, 2011-2018 (NUMBER OF CASES)	38
TABLE 20 U.S. HUMAN CANCER TRENDS, 2011-2018 (NUMBER OF CASES)	38
TABLE 21 CANADIAN HUMAN CANCER TRENDS, 2011-2018 (NUMBER OF CASES)	39
TABLE 22 EUROPEAN HUMAN CANCER TRENDS, 2011-2018 (NUMBER OF CASES)	39
TABLE 23 JAPANESE HUMAN CANCER TRENDS, 2011-2018 (NUMBER OF CASES)	40
TABLE 24 REST OF WORLD HUMAN CANCER TRENDS, 2011-2018 (NUMBER OF CASES)	41
TABLE 25 KNOWN OCCUPATIONAL EXPOSURE RISKS ASSOCIATED WITH CANCER	42
TABLE 26 COLONY-STIMULATING FACTORS ON THE MARKET	48
TABLE 27 SELECTED INTERFERON PRODUCTS ON THE MARKET	49
TABLE 28 SELECTED DEVELOPMENTS IN INTERLEUKINS FOR CANCER THERAPY	51
TABLE 29 SELECTED APPROVED MONOCLONAL ANTIBODIES	52
TABLE 30 ELECTED MABS IN CLINICAL TESTING FOR INITIAL APPROVAL OR FOR ADDITIONAL INDICATIONS	54
TABLE 31 SELECTED CLINICAL TRIALS OF IMMUNOTHERAPY PRODUCTS	63
TABLE 32 GLOBAL MARKET FOR CANCER IMMUNOLOGY BY SEGMENT, THROUGH 2018 (\$ MILLIONS)	85
TABLE 33 VALUE OF CANCER IMMUNOLOGY PRODUCTS IN THE U.S., THROUGH 2018 (\$ MILLIONS)	85
TABLE 34 VALUE OF CANCER IMMUNOLOGY PRODUCTS IN CANADA THROUGH 2018 (\$ MILLIONS)	86
TABLE 35 VALUE OF CANCER IMMUNOLOGY PRODUCTS IN THE EU THROUGH 2018 (\$ MILLIONS)	86

TABLE HEADING	PAGE NO.
TABLE 36 VALUE OF CANCER IMMUNOLOGY PRODUCTS IN JAPAN, THROUGH 2018 (\$ MILLIONS)	87
TABLE 37 VALUE OF CANCER IMMUNOLOGY PRODUCTS FOR REST OF WORLD, (THROUGH 2018) (\$ MILLIONS)	87
TABLE 38 CANCER IMMUNOLOGY MARKET BY INDICATION, THROUGH 2018 (\$ MILLIONS)	88
TABLE 39 CANCER IMMUNOLOGY SALES BY INDICATION (PROSTATE CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 (\$ MILLIONS)	88
TABLE 40 CANCER IMMUNOLOGY SALES BY INDICATION (BREAST CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 (\$ MILLIONS)	89
TABLE 41 CANCER IMMUNOLOGY SALES BY INDICATION (LUNG CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 (\$ MILLIONS)	89
TABLE 42 CANCER IMMUNOLOGY SALES BY INDICATION (BRAIN CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 (\$ MILLIONS)	90
TABLE 43 CANCER IMMUNOLOGY SALES BY INDICATION (HEAD & NECK CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 (\$ MILLIONS)	90
TABLE 44 CANCER IMMUNOLOGY SALES BY INDICATION (OVARIAN CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 (\$ MILLIONS)	91
TABLE 45 CANCER IMMUNOLOGY SALES BY INDICATION (CERVICAL CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 (\$ MILLIONS)	91
TABLE 46 CANCER IMMUNOLOGY SALES BY INDICATION (PANCREATIC CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 (\$ MILLIONS)	91
TABLE 47 CANCER IMMUNOLOGY SALES BY INDICATION (MELANOMA CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 (\$ MILLIONS)	92
TABLE 48 CANCER IMMUNOLOGY SALES BY INDICATION (OTHER CANCERS) AND GEOGRAPHIC REGION, THROUGH 2018 (\$ MILLIONS)	92
TABLE 49 CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: COLONY STIMULATING FACTORS, THROUGH 2018 (\$ MILLIONS)	93
TABLE 50 CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: INTERFERON ALFA AND GAMMA PRODUCTS, THROUGH 2018 (\$ MILLIONS)	93
TABLE 51 CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: INTERLEUKIN PRODUCTS, THROUGH 2018 (\$ MILLIONS)	93
TABLE 52 CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: THERAPEUTIC MONOCLONAL ANTIBODIES, THROUGH 2018 (\$ MILLIONS)	94
TABLE 53 CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: CANCER VACCINES, THROUGH 2018 (\$ MILLIONS)	94
TABLE 54 CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: OTHER CANCER TREATMENT IMMUNOTHERAPY PRODUCTS, THROUGH 2018 (\$ MILLIONS)	95
TABLE 55 GLOBAL ONCOLYTIC VIROTHERAPY MARKET, THROUGH 2023 (\$ MILLIONS)	95
TABLE 56 ONCOLYTIC VIROTHERAPY MARKET BY REGION, THROUGH 2023 (\$ MILLIONS)	96
TABLE 57 ONCOLYTIC VIROLOGY OUTLOOK BY CANCER TYPE, THROUGH 2023 (\$ MILLIONS)	96
TABLE 58 SELECTED PATENTS IN CANCER IMMUNOLOGY AND VIROLOGY, 2005 TO 2013	100

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE CANCER IMMUNOTHERAPIES MARKET BY GEOGRAPHICAL REGION, 2011-2018 (\$ MILLIONS)	7
FIGURE 1 GLOBAL HUMAN CANCER TRENDS, 2011-2018 (NUMBER OF CASES)	38
FIGURE 2 MARKET SHARES OF LEADERS IN CANCER IMMUNOLOGY, 2013 (%)	82